

REFERENCES

44. Davis J C, Dougados M, Braun J, Sieper J, Heijde D, Linden S. Definition of disease duration in ankylosing spondylitis: reassessing the concept. *Ann Rheum Dis* 2006; 65:1518- 1520.
45. Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. *Rheumatology* 2007;46:999-1004.
46. Chen CH, Chen HA, Lu CL, Liao HT, Liu CH, Tsai CY, et al. Association of cigarette smoking with Chinese ankylosing spondylitis patients in Taiwan: a poor disease outcome in systemic inflammation, functional ability, and physical mobility. *Clinical Rheumatology* 2013; 32 (5): 659-663.
47. Reveille JD. HLA-B27 and the seronegative spondyloarthropathies. *Am J Med Sci* 1998;316(4):239-249
48. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. *Best Pract Res Clin Rheumatol*. 2006; 20 (3):451-71.
49. Wade AG, Crawford GM, Pumford N, Koscielny V, Maycock S, McConnachie A. Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation. *BMC Medical Research Methodology* 2001;11: 91-100.
50. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the enthesal pathology in resistant spondylarthropathy. *Arthritis Rheum* 2001;44:2112- 7.
51. McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dunder Y, et al. Adalimumab, etanercept and infliximab for the treatment of